BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

66 related articles for article (PubMed ID: 22331737)

  • 21. [Expression of CA-125 in ovarian cancer].
    Mircea R; Frîncu DL; Dumitrache F
    Rev Med Chir Soc Med Nat Iasi; 2009; 113(4):1191-4. PubMed ID: 20191897
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [CA125].
    Kuzuya K; Kuwabara M; Ariyoshi Y
    Nihon Rinsho; 2005 Aug; 63 Suppl 8():637-41. PubMed ID: 16149599
    [No Abstract]   [Full Text] [Related]  

  • 23. Evaluation of serum tumour markers concentrations in patients with homozygous beta-thalassaemia in relation to demographical, clinical and biochemical parameters.
    Christoforidis A; Lefkou E; Vlachaki E; Perifanis V; Tsatra I; Dogramatzi F; Athanassiou-Metaxa M
    Ann Hematol; 2007 Nov; 86(11):837-41. PubMed ID: 17668208
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Determination of serum tumor markers TPS and CA 15-3 during monitoring of treatment in metastatic breast cancer patients.
    Schuurman JJ; Bong SB; Einarsson R
    Anticancer Res; 1996; 16(4B):2169-72. PubMed ID: 8694538
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Clinical impact of discordance in serum albumin measurements on myeloma international staging system.
    Kapoor P; Snozek CL; Colby C; Larson DR; Katzmann JA; Rajkumar SV; Greipp PR
    J Clin Oncol; 2008 Aug; 26(24):4051-2. PubMed ID: 18711203
    [No Abstract]   [Full Text] [Related]  

  • 26. A multicentre evaluation of the CA 15-3 assay, CA 19-9 assay and CA 125 II assay on the Bayer Immuno 1 System.
    Römer M; Haeckel R; Brux B; Sinha P; Raiko I; Krieg M; Stark M; Seidel D; Hübner U; Schmitz G
    Eur J Clin Chem Clin Biochem; 1997 Aug; 35(8):637-44. PubMed ID: 9298356
    [TBL] [Abstract][Full Text] [Related]  

  • 27. CYFRA 21-1 as a tool for distant metastasis detection in lung cancer.
    Cabrera-Alarcon JL; Carrillo-Vico A; Santotoribio JD; Leon-Justel A; Sanchez-Gil R; Gonzalez-Castro A; Guerrero JM
    Clin Lab; 2011; 57(11-12):1011-4. PubMed ID: 22239035
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Cryptates applied in tumor marker assays (CEA, AFP, CA 15.3, CA19.9): evaluation of Kryptor (Cis-Bio) analyser].
    Gherardi C; Roumier AS; Dubucquoi S; Dessaint JP
    Ann Biol Clin (Paris); 1998; 56(1):92-5. PubMed ID: 9754229
    [No Abstract]   [Full Text] [Related]  

  • 29. Stability of tumor markers CA 19.9, CA 125, and CA 15.3 in serum obtained from plain tubes and tubes containing thixotropic gel separator.
    Banfi G; Parma P; Pontillo M
    Clin Chem; 1997 Dec; 43(12):2430-1. PubMed ID: 9439470
    [No Abstract]   [Full Text] [Related]  

  • 30. [CA125].
    Ariyoshi Y; Kuwabara M; Kuzuya K
    Nihon Rinsho; 1999 Dec; 57 Suppl():455-8. PubMed ID: 10778163
    [No Abstract]   [Full Text] [Related]  

  • 31. Prognostic value of circulating tumor markers in patients with pseudomyxoma peritonei treated with cytoreductive surgery and hyperthermic intraperitoneal chemotherapy.
    Baratti D; Kusamura S; Martinetti A; Seregni E; Laterza B; Oliva DG; Deraco M
    Ann Surg Oncol; 2007 Aug; 14(8):2300-8. PubMed ID: 17510772
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [The characteristics of CA125/MUC16].
    Hiraike O; Yano T; Taketani Y
    Nihon Rinsho; 2010 Jul; 68 Suppl 7():681-4. PubMed ID: 20960850
    [No Abstract]   [Full Text] [Related]  

  • 33. Predictive and prognostic values of cancer-associated serum antigen (CASA) and cancer antigen 125 (CA 125) levels prior to second-look laparotomy for ovarian cancer.
    Kierkegaard O; Mogensen O; Mogensen B; Jakobsen A
    Gynecol Oncol; 1995 Nov; 59(2):251-4. PubMed ID: 7590482
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Multicentre tumour marker reference range study.
    Wilson AP; Van Dalen A; Sibley PE; Kasper LA; Durham AP; el Shami AS
    Anticancer Res; 1999; 19(4A):2749-52. PubMed ID: 10470234
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The tumor marker CA-125 and heart failure.
    Miñana G; Palau P; Núñez J; Sanchis J
    Rev Esp Cardiol; 2010 Oct; 63(10):1213-4. PubMed ID: 20875366
    [No Abstract]   [Full Text] [Related]  

  • 36. Prospective evaluation of CEA and CA 15.3 in patients with locoregional breast cancer.
    Molina R; Filella X; Alicarte J; Zanon G; Pahisa J; Munoz M; Farrus B; Ballesta AM
    Anticancer Res; 2003; 23(2A):1035-41. PubMed ID: 12820344
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Elevated Serum CA-125 concentration in a patient with tuberculous peritonitis mimicking ovarian cancer.
    Kucok M
    J Reprod Med; 1998 Jul; 43(7):635-6. PubMed ID: 9693414
    [No Abstract]   [Full Text] [Related]  

  • 38. Human chorionic gonadotropin and CA 15-3 producing adenocarcinoma.
    Uçkaya G; Ozet A; Arpaci A; Kömürcü S
    Nuklearmedizin; 1998; 37(8):297-8. PubMed ID: 9868713
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [15 years CA-125 antigen: usefulness and limits. Apropos of 3 clinical cases].
    Petignat P; Vajda D; Obrist R
    Praxis (Bern 1994); 1998 Nov; 87(47):1602-5. PubMed ID: 9865132
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Serum CA 125, carcinoembryonic antigen, and CA 19-9 as tumor markers in borderline ovarian tumors.
    Engelen MJ; de Bruijn HW; Hollema H; ten Hoor KA; Willemse PH; Aalders JG; van der Zee AG
    Gynecol Oncol; 2000 Jul; 78(1):16-20. PubMed ID: 10873403
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 4.